Diabetes and obesity have become pressing health issues worldwide. Glucagon-like peptide-1 (GLP-1) receptor agonists, a class ...

In this target trial emulation, glucagon-like peptide-1 receptor agonists (GLP-1RAs) were associated with a lower risk of ...

Some studies link GLP-1 drugs for diabetes with neuroprotective benefits but others say that some of these drugs may increase ...

Diabetes and obesity have become pressing health issues worldwide. Glucagon-like peptide-1 (GLP-1) receptor agonists, a class of medications widely used in the treatment of type 2 diabetes (T2D), have ...

The rise in GLP-1 drugs is undeniable. Morgan Stanley projects that by 2035, 24 million Americans, or 7% of the population, ...

Tirzepatide is just as effective in reducing cardiovascular risk driven by central adiposity as that driven by general ...

Dublin, Feb. 19, 2025 (GLOBE NEWSWIRE) -- The "Glucagon-Like Peptide-1 Receptor (GLP-1R) Agonists in Type 2 Diabetes and Obesity: 68-Market Analysis and Sales Forecast" report has been added to ...

Scientists have discovered an antibody treatment that may help prevent both muscle loss and bone density loss in people using ...

Treatment for OUD is currently dominated by opioid agonist therapies that are highly regulated due to their liability for ...

Many patients with overweight or obesity discontinue glucagon-like peptide-1 (GLP-1) receptor agonist therapy within o ...

Researchers had found in a new study that sodium-glucose cotransporter-2 inhibitors (SGLT-2is) and glucagon-like peptide-1 ...

Like Peptide-1 Receptor (GLP-1R) Agonists in Type 2 Diabetes and Obesity: 68-Market Analysis and Sales Forecast" report has been added to ResearchAndMarkets.com's offering.Across the 68 markets, sales ...